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ABSTRACT
Objective: To map the Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC) onto the EuroQol 5 Dimension (EQ-5D)
utility index in patients with knee osteoarthritis (OA).
Methods: A consecutive sample of patients (n = 258) diagnosed with knee
OA completed both the WOMAC and the EQ-5D. Regression models
with the ordinary least squares (OLS) or the censored least absolute
deviations as the estimator were used to establish the mapping function.
The WOMAC was represented as explanatory variables in four ways: 1)
total score; 2) domain scores (i.e., pain, stiffness, and physical function); 3)
domain scores plus pair-wise interaction terms to account for possible
nonlinearities; and 4) individual item scores. Goodness-of-ﬁt criteria
included the mean absolute error (the primary criterion) and the root mean
squared error, and were obtained using an iterative random sampling
procedure. Prediction precision was evaluated at individual patient level
and at the group level.
Results: The model using the OLS estimator and the WOMAC domain
scores as explanatory variables had the best ﬁt and was chosen as the
preferred mapping model. The prediction error at the individual level
exceeded the maximal tolerance value (i.e., the minimally important dif-
ference of the EQ-5D) in about 16% of the patients. At the group level, the
width of the 95% conﬁdence interval of prediction errors varied from
0.0176 at a sample size of 400 to 0.0359 at a sample size of 100.
Conclusions: EQ-5D scores can be predicted using WOMAC domain
scores with an acceptable precision at both individual and group levels in
patients with mild to moderate knee OA.
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Introduction
Osteoarthritis (OA) is the most common form of arthritis in the
world and affects knees, hip, hands, and spine [1]. Knee and hip
OA in particular are chronic conditions associated with pain and
reduction in physical function, leading to a negative impact on
the physical and psychosocial well-being of patients [2–4]. There-
fore, different instruments have been developed to evaluate the
impact of OA on functioning and quality of life of patients [5].
The Western Ontario and McMaster Universities Osteoarthritis
Index (WOMAC) is one of the most widely used disease-speciﬁc
instruments for knee and hip OA [6]. Its reliability and validity
have been demonstrated in many countries [7].
OA is also imposing a signiﬁcant economic burden to
patients, health-care providers, and the society as a whole [8–14].
To make efﬁcient use of scarce health-care resources, cost-
effectiveness evidence has become more important than ever to
decision-makers at various levels [15–17]. The quality-adjusted
life-year (QALY) is recommended as an outcome measure in
economic evaluations [18–20] as it incorporates both quality and
quantity of life, and allows a broader comparison across treat-
ment strategies, patient populations, and clinical settings. A
utility (as a measure of quality of life) for a health state and the
time duration of staying in that state (as a measure of quantity of
life) are the key parameters for calculating QALY. Utilities can be
deﬁned as a person’s preference or desire for health states and
scaled from 0 (dead) to 1 (full health), with negative values
representing states worse than death. Measuring utilities often
requires generic preference-based health-related quality of life
(HRQoL) instruments, such as the EQ-5D and the Health Utili-
ties Index (HUI). In clinical studies, OA-speciﬁc instruments
(e.g., the WOMAC) are often preferred to generic ones, particu-
larly because of its higher sensitivity in detecting a minimally
important difference (MID) in OA [7,21]. Nevertheless, the
WOMAC (as well as most of other OA-speciﬁc instruments) is a
proﬁle-based measure and thus cannot generate utilities. Given
the fact that most of the patients with OA are elderly and need to
complete a number of administrative forms and disease-speciﬁc
questionnaires during their visits, adding a generic instrument
would cause extra burden (both time and cognitive) on patients
and consequently decrease the quality of the overall response.
Although researchers are struggling to gather utilities that can be
used directly in economic evaluations, a substantial amount of
literature reporting WOMAC scores in different settings and
patient populations is sleeping on the shelves of libraries.
One potential solution to this problem is to map disease-
speciﬁc measures onto generic preference-based indexes so utili-
ties can be estimated using the disease-speciﬁc measures. Some
studies have been published to link the EQ-5Dwith cancer-speciﬁc
measures [22–25], with the ParkinsonDiseaseQuestionnaire [26],
and with inﬂammatory bowel disease-speciﬁc instruments [27].
Barton et al. mapped theWOMAConto EQ-5D scores in patients
with self-reported knee pain [28]. Grootendorst et al. developed a
model to link WOMAC scores with HUI Mark 3 (HUI3) in
patients with knee OA [29]. The aim of this study was to map the
WOMAC onto the EQ-5D in patients with knee OA, which has
Address correspondence to: Feng Xie, Programs for Assessment of Tech-
nology in Health, Department of Clinical Epidemiology and Biostatistics,
McMaster University, 25 Main Street West, Suite 2000, Hamilton, ON,
Canada L8P 1H1. E-mail: fengxie@mcmaster.ca
10.1111/j.1524-4733.2010.00770.x
Volume 13 • Number 8 • 2010
V A L U E I N H E A LT H
© 2010, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 1098-3015/10/873 873–878 873
not been done yet. The EQ-5D was chosen because it is a widely
used generic preference-based instrument and has been demon-
strated as a reliable and valid measure in this patient population
[30–35]. More importantly, these two instruments cover some
common health domains (i.e., pain and physical function) that are
important to patients with knee OA.
Methods
Study Design
A consecutive sample of patients (n = 258) recruited from the
Department of Orthopaedic Surgery at the Singapore General
Hospital between August and December 2005 completed the
questionnaires. All patients were diagnosed with knee OA by
their attending physicians based on clinical and radiographic
features. Each subject was interviewed by a trained interviewer
using the WOMAC and the EQ-5D. The Institutional Review
Board of the hospital approved this study.
Instruments
The WOMAC, a 24-item disease-speciﬁc functioning measure-
ment, consists of three domains, namely, pain (5 items), stiffness
(2 items), and physical function (17 items). Each of these 24
items is graded either on a ﬁve-point Likert scale or on a 100-mm
visual analog scale [6,36]. In this study, we used the Likert scale
WOMAC (version LK 3.0). Items are scored from 0 to 4 (i.e., no,
mild, moderate, severe, and extreme problems). Domain scores
are calculated by summing constituent item scores (i.e., pain
score ranges from 0 to 20, stiffness from 0 to 8, and physical
function from 0 to 68). Total score is calculated by summing the
three domain scores (range 0–96), with higher scores reﬂecting
worse pain, stiffness, and physical function.
The EQ-5D measures HRQoL using a self-classiﬁer. The self-
classiﬁer consists of a ﬁve-item descriptive system and assesses
health status in the domains of mobility, self-care, usual activi-
ties, pain/discomfort, and anxiety/depression [37]. Each item has
three response levels (i.e., no problems, some problems, and
extreme problems). Its psychometric properties have been estab-
lished in patients with OA [30–35].
Statistical Analysis
First, regression analyses using methods suitable for health utility
data, which are often not normally distributed [30,35] and has a
ceiling value of 1.0, were conducted. Regression models ﬁtted
using ordinary least squares (OLS) are consistent regardless of
distribution of outcome measures and have been used in previous
studies [23,28,29]. Nevertheless, some researchers prefer the cen-
sored least absolute deviations (CLAD) estimator to the OLS
based on the argument that a CLAD model accounts for ceiling
values [22,26,38]. The present study used both the OLS and
CLAD estimators.
Second, in the regression analyses, several alternative repre-
sentations of the WOMAC were considered as explanatory vari-
ables: 1) WOMAC total score; 2) WOMAC domain scores (i.e.,
pain, stiffness, and physical function); 3)WOMACdomain scores
plus pair-wise interaction terms (i.e., pain ¥ stiffness, pain ¥
function, stiffness ¥ function, pain ¥ pain, stiffness ¥ stiffness,
and function ¥ function) to account for possible nonlinearities;
and 4) WOMAC individual item scores with stepwise model
selection method in the OLS model, but not in the CLAD model.
The reasons for including or excluding demographics in regression
models varied across the published studies. To maintain the
consistency with other published studies mapping disease-speciﬁc
instruments to the EQ-5D [22,23,26], demographics were not
included in the analysis. Nevertheless, the impact of including
demographics on predicting utilities is an important area to be
explored in future studies. The outcome variablewas EQ-5D score
calculated using the Japanese scoring algorithm [39].
A number of criteria were used to examine the goodness of ﬁt
of each model [29]. Mean absolute error (MAE) is the average of
the absolute difference between observed and predicted values. In
the present study, MAE was identiﬁed as the primary criterion for
goodness of ﬁt as it is an easily and a directly interpretable
measure. We also reported the root mean squared error (RMSE),
the positive square root of the average squared prediction error.
In contrast to MAE, RMSE attaches greater weight to larger
errors. To account for variability in these goodness-of-ﬁt diag-
nostics, an iterative random sampling procedure proposed by
Grootendorst et al. [29] was used. Speciﬁcally, the whole sample
was randomly split into two groups, one for estimation and the
other for validation. The estimation sample was used to ﬁt each
candidate model, and the validation sample was used to obtain
the MAE and RMSE. This process was repeated 500 times, each
time, with a random split, generating 500 MAEs and RMSEs.
Mean MAE, mean RMSE, and corresponding 95% conﬁdence
intervals (CIs) were calculated. The lower the mean MAE and
RMSE, the better the goodness of ﬁt of a model. The preferred
model was the one with the best goodness of ﬁt. We presented
one random split as an illustration.
Finally, the coefﬁcients of the preferred model were deter-
mined using the whole study sample. The precision of this pre-
ferred model was examined at two levels. At the individual level,
the prediction error was computed using the difference between
observed and predicted EQ-5D scores for each of the 258
patients. At the group level, the prediction error was estimated by
applying a nonparametric bootstrapping with replacement
method [29]. Speciﬁcally, various group sizes of patients (n = 50,
100, 200, and 400) were randomly sampled. For example, a
patient was randomly chosen from the original data set and
his/her predicted EQ-5D score and prediction error were
recorded. This patient was then placed back into the data set
(hence the term “with replacement”). This process was repeated
until the sample size of each group (i.e., n = 50, 100, 200, and
400) was reached. For each group, mean predicted EQ-5D
scores and mean prediction error were calculated, which formed
one bootstrapping replicate. By repeating the above-mentioned
process 5000 times, we generated a distribution for the group
mean predicted EQ-5D scores and corresponding group mean
prediction errors for each of the groups. The 2.5th and 97.5th
percentiles of the distribution were therefore used to estimate the
95% CI for the prediction error.
All statistical tests were two sided and conducted at a signiﬁ-
cance level of 5%. Data were analyzed using R version 2.4.1 (the
R Development Core Team).
Results
Descriptive Summary
As shown in Table 1, the mean age of the whole sample was 66.5
years with 83% being female. The mean EQ-5D score was 0.62,
whereas the meanWOMAC pain, stiffness, and physical function
scores were 6.64, 3.12, and 26.24, respectively, for the cohort.
Model Selection
Table 2 compares the goodness of ﬁt of the regression models
with different representations of the WOMAC. When using the
OLS as the estimator, the model—utilizing the three WOMAC
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domain scores as the explanatory variables—had the lowest
MAE (i.e., 0.074) and RMSE (i.e., 0.095) values. This result was
consistent when using the CLAD as the estimator. The model
with the WOMAC domain scores as the explanatory variables
and the OLS as the estimator had the best goodness of ﬁt (i.e., the
preferred model) according to the criteria (i.e., lowest MAE and
RMSE values). As an illustration, Table 3 compares the observed
and predicted EQ-5D scores by the OLS model in one of the
randomly generated validation samples. The EQ-5D scores pre-
dicted by the CLAD model were also presented for comparison
purpose. The mean observed EQ-5D score was 0.624 compared
with 0.604 predicted by the OLS model and 0.600 by the CLAD
model. The standard deviation (SD) of the observed scores was
higher than the SD of the predicted scores by both models. Again,
the OLS model generated lower MAE than the CLAD model did
in the validation sample.
Speciﬁcation of the Preferred Model
Based on the performances of each candidate model, the model
using the OLS estimator and the WOMAC domain scores as
explanatory variables was chosen as the preferred mapping
model. The coefﬁcients were therefore obtained by applying this
model to the whole sample.
EQ-5D = 0.83414 - 0.00166 ¥ WOMAC pain score - 0.00092 ¥
WOMAC stiffness score - 0.00330 ¥ WOMAC function score
The adjusted R2 for this preferred model was 0.449. For
example, if a patient has WOMAC pain, stiffness, and function
scores of 10, 4, and 20, respectively, this model will estimate an
EQ-5D score of 0.7512 for that patient.
Prediction Precision of the Preferred Model at the
Individual Level
Table 4 presents the number and percentage of patients for which
the absolute difference between the predicted and the observed
EQ-5D scores fell into various ranges. The MIDs of the EQ-5D
were reported as 0.07 across different patient populations and as
0.12 in patients with knee OA [40]. Approximately 57% and
84% of the absolute differences between the observed and pre-
dicted EQ-5D scores in the OLS model were less than 0.07 and
0.12, respectively. The corresponding percentages for the CLAD
model were 56% and 83% (Table 4).
Prediction Precision of the Preferred Model at the
Group Level
The OLS model produced acceptable prediction precision at the
individual level. At the group level, most of the predictions were
between 0.55 and 0.65 (Fig. 1). The proportion of predictions
that fell in this range increased with group size (i.e., n = 50, 100,
200, and 400), whereas the errors of the predictions shrank with
group size (Fig. 1). The 95% CI of the prediction errors ranged
from -0.025 to 0.026 at a group size of 50 and from -0.013 to
0.013 at a group size of 400 (Table 5). No prediction error for
the group sizes exceeded the MID of the EQ-5D in knee OA
patients. As shown in Table 5, the prediction precision can be
estimated according to the group size and mean predicted EQ-5D
score. To illustrate, if the mean predicted EQ-5D score was 0.62
in a group of 200 patients, 95% CI of group-level prediction
would be from 0.606 (i.e., 0.62–0.0140) to 0.627 (i.e.,
0.62 + 0.0070).
Table 1 Demographic characteristics and quality of life scores for the
study sample
Total sample
(n = 258)
Demographic characteristics
Age, mean (SD) 66.5 (7.6)
Female, n (%) 213 (83)
Ethnicity, n (%)
Chinese 230 (891)
Malay 10 (5)
Indian 14 (5)
Others 3 (1)
Formal education, n (%)
<1 year 107 (43)
1–6 years 85 (34)
7–10 years 46 (18)
>10 years 14 (6)
Married, n (%) 235 (92)
Retirees/homemaker, n (%) 222 (86.0)
BMI, mean (SD) 28.2 (4.7)
Years with OA, mean (SD) 6 (5.2)
EQ-5D scores, mean (SD) 0.62 (0.13)
WOMAC scores, mean (SD)
Pain 6.64 (3.38)
Stiffness 3.12 (2.02)
Function 26.24 (10.18)
BMI, body mass index; EQ-5D, EuroQol 5 Dimension; SD, standard deviation; OA, osteoar-
thritis;WOMAC,Western Ontario and McMaster Universities Osteoarthritis Index.
Table 2 Model selection diagnostics estimated using the iterative random sampling procedure*
Outcome variable
EQ-5D
Explanatory variables:WOMAC
Total score Domain scores Domains plus interactions Item scores†
OLS model
MAE 0.0750 (0.0671, 0.0822) 0.0736 (0.0654, 0.0809) 0.0780 (0.0702, 0.0870) 0.0773 (0.0682, 0.0870)
RMSE 0.0967 (0.0839, 0.1075) 0.0947 (0.0825, 0.1052) 0.1013 (0.0879, 0.1161) 0.0997 (0.0873, 0.1127)
CLAD model
MAE 0.0756 (0.0678, 0.0833) 0.0745 (0.0665, 0.0823) 0.0794 (0.0703, 0.0896)
RMSE 0.0975 (0.0847, 0.1090) 0.0956 (0.0841, 0.1072) 0.1040 (0.0890, 0.1244)
*Mean estimates with 95% conﬁdence intervals displayed in parentheses.
†CLAD model cannot perform stepwise selection.
EQ-5D, EuroQol 5 Dimension;WOMAC,Western Ontario and McMaster Universities Osteoarthritis Index; OLS, ordinary least squares; MAE, mean absolute error; RMSE, root mean squared
error; CLAD, censored least absolute deviations.
Table 3 Performance of regression models using a validation sample
EQ-5D Observed CLAD OLS
Mean 0.6238 0.6001 0.6040
Median 0.6490 0.6086 0.6105
SD 0.1256 0.0688 0.0725
MAE 0.0743 0.0716
EQ-5D, EuroQol 5 Dimension;CLAD, censored least absolute deviations;OLS, ordinary least
squares; SD, standard deviation; MAE, mean absolute error.
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Discussion
Clinical evidence forms the foundation of economic evaluation in
health-care programs. Preference-based HRQoL instruments are
not being used as often as disease-speciﬁc instruments in clinical
studies. This could be a potential barrier to conducting an eco-
nomic evaluation that allows broader comparison across differ-
ent diseases for decision-makers. In an attempt to reduce this
barrier by making use of existing clinical evidence obtained from
disease-speciﬁc instruments, we compared the performance of
different regression models mapping WOMAC scores onto
EQ-5D utilities. The model using the three WOMAC domain
scores as the explanatory variables and the OLS as the estimator
is the preferred model with the best goodness of ﬁt (i.e., the
lowest prediction error) compared with the alternative models.
Several issues on generalizability are worth noting for the
present model-based study. First, the mapping model is recom-
mended for use in patients with mild to moderate knee OA as this
is the population used to build the model. Arbitrarily, using the
median WOMAC domain scores as thresholds of severity (i.e.,
10 for pain, 4 for stiffness, and 34 for physical function), the
mean MAE was higher in a subgroup of severe patients than in
patients with mild or moderate disease. Thus, generalizing the
model to severe patients may be questionable. Second, although
this mapping model can be used for both individual and group
level predictions, application at the group level would be pre-
ferred because effectiveness in economic evaluations is usually
compared at the group level. Notably, at the group level, the
width of 95% CI of prediction errors varied from 0.0176 at a
sample size of 400 to 0.0359 at a sample size of 100. Given the
sample size range often seen in clinical studies in OA, the pre-
diction precision is deemed to be good. Nevertheless, the caveat
is that the prediction error could be increased when the mapping
model is used in an economic evaluation with QALY being
estimated over a relatively longer period of time. Therefore, it is
highly recommended that 95% CI of the prediction be used in
Table 4 Prediction precision of the preferred model at the individual
level
|Difference|
CLAD (comparison)
n (%)
OLS (preferred model)
n (%)
|| 0.01 23 (8.9) 23 (8.9)
0.01 < || 0.03 43 (16.7) 49 (19.1)
0.03 < || 0.05 44 (17.1) 35 (13.6)
0.05 < || 0.07 34 (13.2) 40 (15.6)
0.07 < || 0.10 47 (18.3) 44 (17.1)
0.10 < || 0.12 23 (8.9) 24 (9.3)
|| > 0.12 43 (16.7) 42 (16.3)
CLAD, censored least absolute deviations; OLS, ordinary least squares.
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Figure 1 Prediction precision of the preferred
model at the group level. EQ-5D, EuroQol 5
Dimension.
Table 5 Comparison of group mean predicted versus group mean pre-
diction error of the preferred model
Range of
predicted mean
EQ-5D score
Group
size
Lower 95% CI
of prediction
error distribution
Upper 95% CI
of prediction
error distribution CI width
0.5–0.6 50 -0.0244 0.0224 0.0468
0.6–0.7 50 -0.0253 0.0262 0.0515
0.5–0.6 100 -0.0134 0.0161 0.0295
0.6–0.7 100 -0.0177 0.0182 0.0359
0.5–0.6 200 0.0055 0.0320 0.0265
0.6–0.7 200 -0.0140 0.0070 0.0210
0.5–0.6 400 -0.0131 0.0128 0.0259
0.6–0.7 400 -0.0083 0.0093 0.0176
EQ-5D, EuroQol 5 Dimension; CI, conﬁdence interval.
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sensitivity analyses to examine the potential impact on decision-
making. Lastly, the present study was based on a sample of Asian
patients, and caution should be exercised when applying this
mapping model to estimate utilities of other patient populations.
Nevertheless, the mapping model is of value in predicting utilities
for patients with mild to moderate knee OA when such data are
not available.
To date, only two published studies mapped the WOMAC
onto preference-based HRQoL instruments [28,29]. Compared
with our model, the preferred model in the study by Barton et al.
[28] had higher MAE and RMSE values (i.e., 0.129 and 0.180,
respectively, vs. 0.074 and 0.095 in our study), and lower
adjusted R2 (0.313 vs. 0.449 in our study). Notably, these two
studies differed in the patient population (i.e., the patients with
conﬁrmed knee OA vs. the patients with knee pain); the scoring
algorithms (UK vs. Japan); the WOMAC representations; and
the model estimators. Our model also has better goodness of ﬁt
in terms of the MAE and RMSE values than the model mapping
the WOMAC onto the HUI3 [29].
It is always a good practice to have an independent data set
with both WOMAC and EQ-5D scores available to assess exter-
nal validity of the mapping model. This important property was
not evaluated in the present study because of the lack of such
data. Nevertheless, it is still worth reporting the mapping func-
tion from the present study while keeping this limitation in mind.
Second, the mapping function was developed based on cross-
sectional data. It is not clear if and how the mapping function
varies over time. Nevertheless, the main application of the
function is to generate utilities for economic evaluations, which
typically compare different treatments over time. Thus, the lon-
gitudinal validity of the function needs to be assessed before it
can be applied in economic evaluations. Last but not least, uncer-
tainty is an important issue to be addressed in economic evalu-
ations. Notably, about 50% of the variance around the estimates
cannot be explained by the function. It is likely that use of the
mapping function increases the uncertainty around utility esti-
mates. Therefore, the mapping function is by no means a replace-
ment of the EQ-5D in economic evaluations. Instead, this
function is intended to serve as a remedy when the EQ-5D score
(or utility) is important but not available. The uncertainty intro-
duced by the mapping function itself should also be adequately
addressed.
In conclusion, EQ-5D scores can be predicted using
WOMAC domain scores with an acceptable precision at indi-
vidual and group levels in patients with mild to moderate knee
OA. Factors including patient population, sample size, and tol-
erance level of the prediction error must be carefully considered
and balanced when applying this mapping function.
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